- Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
- Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology to Participate in Upcoming Investor Conferences in May
- Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
- Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
- Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
- Olema Oncology to Participate in Upcoming Investor Conferences
- Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
More ▼
Key statistics
On Thursday, Olema Pharmaceuticals Inc (OLMA:NSQ) closed at 8.73, 73.90% above the 52 week low of 5.02 set on May 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.27 |
---|---|
High | 9.34 |
Low | 8.60 |
Bid | 3.51 |
Offer | 12.49 |
Previous close | 8.73 |
Average volume | 753.73k |
---|---|
Shares outstanding | 55.93m |
Free float | 53.81m |
P/E (TTM) | -- |
Market cap | 488.30m USD |
EPS (TTM) | -2.02 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼